Moving the Meter on Ovarian Cancer

Marijke Vroomen Durning, RN
Published: Friday, Dec 02, 2016
Michael J. Birrer, MD, PhD

Michael J. Birrer, MD, PhD

Despite a decrease in the diagnosis of ovarian cancer and in the number of deaths due to the malignancy in the United States over the past 25 years, the disease remains a silent killer that is responsible for approximately 14,000 deaths every year.1 The 5-year survival rate stands at about 46.2%, significantly lower than the 90% rate for breast cancer, the 80% for endometrial cancer, and the nearly 70% for cervical cancer.1,2

“I hope that now we will have PARP inhibitors, some combinations of PARP inhibitors with other drugs, like antiangiogenic drugs. We’re already doing trials with that,” Mirza said. “We’re really in a very interesting era, and we’re seeing some major gains for our patients.”

PARP Inhibitors Reshaping the Field

A flurry of research findings in recent weeks shows how vital PARP inhibitors as an emerging class of agents have become to the development of new treatments for patients with ovarian cancer. The field has blossomed with 1 approved drug and at least 4 other agents undergoing clinical trials.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication